$XRTX News

XORTX Meets Nasdaq Continued Listing Requirements

XORTX Therapeutics shares are trading higher after the company announced that it regained Nasdaq compliance.

XORTX Therapeutics shares are trading higher after the company announced that it regained Nasdaq compliance.

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

XORTX Confirms Effective Date of Share Consolidation

XORTX Therapeutics shares are trading lower after the company announced the delay of its 1-for-5 reverse stock split to April 6, 2026.

XORTX Announces Results of Annual and Special Meeting of Shareholders

XORTX Announces Change of Effective Date of Share Consolidation

XORTX Therapeutics shares are trading higher after the company announced it delayed its 1-for-5 shares consolidation.

XORTX Announces Share Consolidation

XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting

XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders

XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

XORTX Therapeutics Says Published Research Supports Company Approach to Gout Treatment

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

XORTX Announces Closing of US$1.1 Million Registered Direct Offering

XORTX Therapeutics Down Near 10% In US Premarket As Prices US$1.1 Million Registered Direct Offering